메뉴 건너뛰기




Volumn 10, Issue 6, 2013, Pages 336-344

Potential biofluid markers and treatment targets for renal cell carcinoma

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOPHILIN; AQUAPORIN 1; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CYCLIN D; ENTINOSTAT; ERYTHROPOIETIN; EVEROLIMUS; EXPORTIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDOLEAMINE 2,3 DIOXYGENASE; KIDNEY INJURY MOLECULE 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MICRORNA; MICRORNA 378; MICRORNA 451; MYC PROTEIN; PAZOPANIB; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN 14 3 3; QUINOLINIC ACID; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRYPTOPHAN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VORINOSTAT;

EID: 84880273186     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.52     Document Type: Review
Times cited : (24)

References (137)
  • 1
    • 80052270947 scopus 로고    scopus 로고
    • The epidemiology of renal cell carcinoma
    • Ljungberg, B. et al. The epidemiology of renal cell carcinoma. Eur. Urol. 60, 615-621 (2011
    • (2011) Eur. Urol , vol.60 , pp. 615-621
    • Ljungberg, B.1
  • 2
    • 84860223568 scopus 로고    scopus 로고
    • Annual Report to the Nation on the status of cancer 1975 2008, featuring cancers associated with excess weight and lack of sufficient physical activity
    • Eheman, C. et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 118, 2338-2366 (2012
    • (2012) Cancer , vol.118 , pp. 2338-2366
    • Eheman, C.1
  • 3
    • 13244267017 scopus 로고    scopus 로고
    • Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies
    • Hunt, J. D., van der Hel, O. L., McMillan, G. P., Boffetta, P. & Brennan, P. Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies. Int. J. Cancer 114, 101-108 (2005
    • (2005) Int. J. Cancer , vol.114 , pp. 101-108
    • Hunt, J.D.1    Van Der Hel, O.L.2    McMillan, G.P.3    Boffetta, P.4    Brennan, P.5
  • 4
    • 77953666412 scopus 로고    scopus 로고
    • Molecularly targeted agents for renal cell carcinoma: The next generation
    • Cowey, C. L. & Hutson, T. E. Molecularly targeted agents for renal cell carcinoma: The next generation. Clin. Adv. Hematol. Oncol. 8, 357-364 (2010
    • (2010) Clin. Adv. Hematol. Oncol , vol.8 , pp. 357-364
    • Cowey, C.L.1    Hutson, T.E.2
  • 5
    • 84861133861 scopus 로고    scopus 로고
    • RCDB: Renal cancer gene database
    • Ramana, J. RCDB: Renal Cancer Gene Database. BMC Res. Notes 5, 246 (2012
    • (2012) BMC Res. Notes 5 , vol.246
    • Ramana, J.1
  • 6
    • 33845711356 scopus 로고    scopus 로고
    • Cancer incidence before and after kidney transplantation
    • Vajdic, C. M. et al. Cancer incidence before and after kidney transplantation. JAMA 296, 2823-2831 (2006
    • (2006) JAMA , vol.296 , pp. 2823-2831
    • Vajdic, C.M.1
  • 7
    • 70349498763 scopus 로고    scopus 로고
    • The pattern of excess cancer in dialysis and transplantation
    • Stewart, J. H. et al. The pattern of excess cancer in dialysis and transplantation. Nephrol. Dial. Transplant. 24, 3225-3231 (2009
    • (2009) Nephrol. Dial. Transplant , vol.24 , pp. 3225-3231
    • Stewart, J.H.1
  • 8
    • 77952248366 scopus 로고    scopus 로고
    • Epidemiology and risk factors for kidney cancer
    • Chow, W. H., Dong, L. M. & Devesa, S. S. Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol. 7, 245-257 (2010
    • (2010) Nat. Rev. Urol , vol.7 , pp. 245-257
    • Chow, W.H.1    Dong, L.M.2    Devesa, S.S.3
  • 10
    • 0029871708 scopus 로고    scopus 로고
    • Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine
    • Muslin, A. J., Tanner, J. W., Allen, P. M. & Shaw, A. S. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84, 889-897 (1996
    • (1996) Cell , vol.84 , pp. 889-897
    • Muslin, A.J.1    Tanner, J.W.2    Allen, P.M.3    Shaw, A.S.4
  • 11
    • 0032474838 scopus 로고    scopus 로고
    • A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity
    • Tzivion, G., Luo, Z. & Avruch, J. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 394, 88-92 (1998
    • (1998) Nature , vol.394 , pp. 88-92
    • Tzivion, G.1    Luo, Z.2    Avruch, J.3
  • 12
    • 0030584088 scopus 로고    scopus 로고
    • Serine phosphorylation of death agonist bad in response to survival factor results in binding to 14-3-3 not bcl-x(l
    • Zha, J., Harada, H., Yang, E., Jockel, J. & Korsmeyer, S. J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87, 619-628 (1996
    • (1996) Cell , vol.87 , pp. 619-628
    • Zha, J.1    Harada, H.2    Yang, E.3    Jockel, J.4    Korsmeyer, S.J.5
  • 13
    • 0033587773 scopus 로고    scopus 로고
    • Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins
    • Zhang, L., Chen, J. & Fu, H. Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. Proc. Natl Acad. Sci. USA 96, 8511-8515 (1999
    • (1999) Proc. Natl Acad. Sci. USA , vol.96 , pp. 8511-8515
    • Zhang, L.1    Chen, J.2    Fu, H.3
  • 14
    • 79960561810 scopus 로고    scopus 로고
    • 14-3-3 protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid
    • Minamida, S. et al. 14-3-3 protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid. Anal. Bioanal. Chem. 401, 245-252 (2011
    • (2011) Anal. Bioanal. Chem , vol.401 , pp. 245-252
    • Minamida, S.1
  • 15
    • 72849149047 scopus 로고    scopus 로고
    • Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation
    • Liang, S. et al. Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation. Electrophoresis 30, 4152-4162 (2009
    • (2009) Electrophoresis , vol.30 , pp. 4152-4162
    • Liang, S.1
  • 16
    • 0032512724 scopus 로고    scopus 로고
    • Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury
    • Ichimura, T. et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. 273, 4135-4142 (1998
    • (1998) J. Biol. Chem , vol.273 , pp. 4135-4142
    • Ichimura, T.1
  • 17
    • 1242343823 scopus 로고    scopus 로고
    • Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury
    • Ichimura, T. Hung, C. C., Yang, S. A., Stevens, J. L. & Bonventre, J. V. Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. 286, F552-F563 (2004
    • (2004) Am. J. Physiol , vol.286
    • Ichimura, T.1    Hung, C.C.2    Yang, S.A.3    Stevens, J.L.4    Bonventre, J.V.5
  • 18
    • 0036314217 scopus 로고    scopus 로고
    • Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury
    • Han, W. K. Bailly, V., Abichandani, R., Thadhani, R. & Bonventre, J. V. Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int. 62, 237-244 (2002
    • (2002) Kidney Int , vol.62 , pp. 237-244
    • Han, W.K.1    Bailly, V.2    Abichandani, R.3    Thadhani, R.4    Bonventre, J.V.5
  • 19
    • 34948814501 scopus 로고    scopus 로고
    • Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region
    • Zhang, Z., Humphreys, B. D. & Bonventre, J. V. Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region. J. Am. Soc. Nephrol. 18, 2704-2714 (2007
    • (2007) J. Am. Soc. Nephrol , vol.18 , pp. 2704-2714
    • Zhang, Z.1    Humphreys, B.D.2    Bonventre, J.V.3
  • 20
    • 24344507726 scopus 로고    scopus 로고
    • Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma
    • Han, W. K. et al. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J. Am. Soc. Nephrol. 16, 1126-1134 (2005
    • (2005) J. Am. Soc. Nephrol , vol.16 , pp. 1126-1134
    • Han, W.K.1
  • 21
    • 80052945596 scopus 로고    scopus 로고
    • Urine Metabolomics For kidney Cancer Detection And Biomarker Discovery
    • Ganti, S. & Weiss, R. H. Urine metabolomics for kidney cancer detection and biomarker discovery. Urol. Oncol. 29, 551-557 (2011
    • (2011) Urol. Oncol , vol.29 , pp. 551-557
    • Ganti, S.1    Weiss, R.H.2
  • 22
    • 0036690151 scopus 로고    scopus 로고
    • Endogenous kynurenines as targets for drug discovery and development
    • Stone, T. W. & Darlington, L. G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 1, 609-620 (2002
    • (2002) Nat. Rev. Drug Discov , vol.1 , pp. 609-620
    • Stone, T.W.1    Darlington, L.G.2
  • 23
    • 16744366213 scopus 로고    scopus 로고
    • VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation
    • Brauch, H. et al. VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 60, 1942-1948 (2000
    • (2000) Cancer Res , vol.60 , pp. 1942-1948
    • Brauch, H.1
  • 24
    • 12444279265 scopus 로고
    • On the origin of cancer cells
    • Warburg, O. On the origin of cancer cells. Science 123, 309-314 (1956
    • (1956) Science , vol.123 , pp. 309-314
    • Warburg, O.1
  • 26
    • 38649107388 scopus 로고    scopus 로고
    • Ido-expressing regulatory dendritic cells in cancer and chronic infection
    • Popov, A. & Schultze, J. L. IDO-expressing regulatory dendritic cells in cancer and chronic infection. J. Mol. Med. 86, 145-160 (2008
    • (2008) J. Mol. Med , vol.86 , pp. 145-160
    • Popov, A.1    Schultze, J.L.2
  • 27
    • 80052016154 scopus 로고    scopus 로고
    • IDO: More than an enzyme
    • Chen, W. IDO: More than an enzyme. Nat. Immunol. 12, 809-811 (2011
    • (2011) Nat. Immunol , vol.12 , pp. 809-811
    • Chen, W.1
  • 28
    • 76249093444 scopus 로고    scopus 로고
    • Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance
    • Godin-Ethier, J. et al. Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J. Immunol. 183, 7752-7760 (2009
    • (2009) J. Immunol , vol.183 , pp. 7752-7760
    • Godin-Ethier, J.1
  • 29
    • 77951744263 scopus 로고    scopus 로고
    • Urinary biomarkers for the early diagnosis of kidney cancer
    • Morrissey, J. J., London, A. N., Luo, J. & Kharasch, E. D. Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clin. Proc. 85, 413-421 (2010
    • (2010) Mayo Clin. Proc , vol.85 , pp. 413-421
    • Morrissey, J.J.1    London, A.N.2    Luo, J.3    Kharasch, E.D.4
  • 30
    • 69249220223 scopus 로고    scopus 로고
    • Expression of aquaporin 1 in primary renal tumors: A prognostic indicator for clear-cell renal cell carcinoma
    • Huang, Y. et al. Expression of aquaporin 1 in primary renal tumors: A prognostic indicator for clear-cell renal cell carcinoma. Eur. Urol. 56, 690-698 (2009
    • (2009) Eur. Urol , vol.56 , pp. 690-698
    • Huang, Y.1
  • 31
    • 0032548878 scopus 로고    scopus 로고
    • Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy
    • Takenawa, J. et al. Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy. Int. J. Cancer 79, 1-7 (1998
    • (1998) Int. J. Cancer , vol.79 , pp. 1-7
    • Takenawa, J.1
  • 32
    • 13844254987 scopus 로고    scopus 로고
    • Gene expression analysis of renal carcinoma: Adipose differentiation- related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma
    • Yao, M. et al. Gene expression analysis of renal carcinoma: Adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J. Pathol. 205, 377-387 (2005
    • (2005) J. Pathol , vol.205 , pp. 377-387
    • Yao, M.1
  • 33
    • 33846289955 scopus 로고    scopus 로고
    • Expression of adipose differentiation-related protein: A predictor of cancer-specific survival in clear cell renal carcinoma
    • Yao, M. et al. Expression of adipose differentiation-related protein: A predictor of cancer-specific survival in clear cell renal carcinoma. Clin. Cancer Res. 13, 152-160 (2007
    • (2007) Clin. Cancer Res , vol.13 , pp. 152-160
    • Yao, M.1
  • 34
    • 0020376310 scopus 로고
    • Prognostic significance of morphologic parameters in renal cell carcinoma
    • Fuhrman, S. A., Lasky, L. C. & Limas, C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol. 6, 655-663 (1982
    • (1982) Am. J. Surg. Pathol , vol.6 , pp. 655-663
    • Fuhrman, S.A.1    Lasky, L.C.2    Limas, C.3
  • 35
    • 0036151647 scopus 로고    scopus 로고
    • Renal epithelial neoplasms: The diagnostic implications of electron microscopic study in 55 cases
    • Krishnan, B. & Truong, L. D. Renal epithelial neoplasms: The diagnostic implications of electron microscopic study in 55 cases. Hum. Pathol. 33, 68-79 (2002
    • (2002) Hum. Pathol , vol.33 , pp. 68-79
    • Krishnan, B.1    Truong, L.D.2
  • 36
    • 77955158430 scopus 로고    scopus 로고
    • Pathway signature and cellular differentiation in clear cell renal cell carcinoma
    • Tun, H. W. et al. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS ONE 5, e10696 (2010
    • (2010) PLoS ONE , vol.5
    • Tun, H.W.1
  • 37
    • 84855447249 scopus 로고    scopus 로고
    • MicroRNAs: Processing, maturation, target recognition and regulatory functions
    • Shukla, G. C., Singh, J. & Barik, S. MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol. Cell. Pharmacol. 3, 83-92 (2011
    • (2011) Mol. Cell. Pharmacol , vol.3 , pp. 83-92
    • Shukla, G.C.1    Singh, J.2    Barik, S.3
  • 38
    • 77954932826 scopus 로고    scopus 로고
    • Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis
    • Gerin, I. et al. Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis. Am. J. Physiol. Endocrinol. Metab. 299, E198-E206 (2010
    • (2010) Am. J. Physiol. Endocrinol. Metab , vol.299
    • Gerin, I.1
  • 39
    • 81555212723 scopus 로고    scopus 로고
    • Cardiac insulin resistance and microRNA modulators
    • Pulakat, L., Aroor, A. R., Gul, R. & Sowers, J. R. Cardiac insulin resistance and microRNA modulators. Exp. Diabetes Res. 2012, 654904 (2012
    • (2012) Exp. Diabetes Res , vol.2012 , pp. 654904
    • Pulakat, L.1    Aroor, A.R.2    Gul, R.3    Sowers, J.R.4
  • 40
    • 38049103266 scopus 로고    scopus 로고
    • MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression
    • Lee, D. Y., Deng, Z., Wang, C. H. & Yang, B. B. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc. Natl Acad. Sci. USA 104, 20350-20355 (2007
    • (2007) Proc. Natl Acad. Sci. USA , vol.104 , pp. 20350-20355
    • Lee, D.Y.1    Deng, Z.2    Wang, C.H.3    Yang, B.B.4
  • 41
    • 48749122914 scopus 로고    scopus 로고
    • Circulating microRNAs as stable blood-based markers for cancer detection
    • Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513-10518 (2008
    • (2008) Proc. Natl Acad. Sci. USA , vol.105 , pp. 10513-10518
    • Mitchell, P.S.1
  • 42
    • 72449180374 scopus 로고    scopus 로고
    • Circulating micrornas in breast cancer and healthy subjects
    • Zhu, W., Qin, W., Atasoy, U. & Sauter, E. R. Circulating microRNAs in breast cancer and healthy subjects. BMC Res. Notes 2, 89 (2009
    • (2009) BMC Res. Notes , vol.2 , pp. 89
    • Zhu, W.1    Qin, W.2    Atasoy, U.3    Sauter, E.R.4
  • 43
    • 57649091633 scopus 로고    scopus 로고
    • The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform
    • Resnick, K. E. et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112, 55-59 (2009
    • (2009) Gynecol. Oncol , vol.112 , pp. 55-59
    • Resnick, K.E.1
  • 44
    • 84858712300 scopus 로고    scopus 로고
    • Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma
    • Redova, M. et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Translat. Med. 10, 55 (2012
    • (2012) J. Translat. Med , vol.10 , pp. 55
    • Redova, M.1
  • 45
    • 77649259296 scopus 로고    scopus 로고
    • MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells
    • Godlewski, J. et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 37, 620-632 (2010
    • (2010) Mol. Cell , vol.37 , pp. 620-632
    • Godlewski, J.1
  • 46
    • 84856018708 scopus 로고    scopus 로고
    • Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer
    • Liu, H. et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 316, 196-203 (2012
    • (2012) Cancer Lett , vol.316 , pp. 196-203
    • Liu, H.1
  • 47
    • 84864055685 scopus 로고    scopus 로고
    • Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients
    • Song, J. et al. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig. Dis. Sci. 57, 897-904 (2012
    • (2012) Dig. Dis. Sci , vol.57 , pp. 897-904
    • Song, J.1
  • 48
    • 55549134997 scopus 로고    scopus 로고
    • Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): A benchmark for emerging targeted cancer therapies
    • Belldegrun, A. S. et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): A benchmark for emerging targeted cancer therapies. Cancer 113, 2457-2463 (2008
    • (2008) Cancer , vol.113 , pp. 2457-2463
    • Belldegrun, A.S.1
  • 49
    • 0030795733 scopus 로고    scopus 로고
    • Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site
    • Muller, Y. A. et al. Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl Acad. Sci. USA 94, 7192-7197 (1997
    • (1997) Proc. Natl Acad. Sci. USA , vol.94 , pp. 7192-7197
    • Muller, Y.A.1
  • 51
    • 51049084870 scopus 로고    scopus 로고
    • Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors
    • Nickerson, M. L. et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 14, 4726-4734 (2008
    • (2008) Clin. Cancer Res , vol.14 , pp. 4726-4734
    • Nickerson, M.L.1
  • 52
    • 33644657042 scopus 로고    scopus 로고
    • Kidney cancer: Identification of novel targets for therapy
    • Weiss, R. H. & Lin, P. Y. Kidney cancer: Identification of novel targets for therapy. Kidney Int. 69, 224-232 (2006
    • (2006) Kidney Int , vol.69 , pp. 224-232
    • Weiss, R.H.1    Lin, P.Y.2
  • 53
    • 0030895147 scopus 로고    scopus 로고
    • Vascular endothelial growth factor expression is increased in renal cell carcinoma
    • Nicol, D. et al. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J. Urol. 157, 1482-1486 (1997
    • (1997) J. Urol , vol.157 , pp. 1482-1486
    • Nicol, D.1
  • 54
    • 4944249117 scopus 로고    scopus 로고
    • BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    • Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004
    • (2004) Cancer Res , vol.64 , pp. 7099-7109
    • Wilhelm, S.M.1
  • 55
    • 76249126867 scopus 로고    scopus 로고
    • Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma
    • Huang, D. et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 70, 1053-1062 (2010
    • (2010) Cancer Res , vol.70 , pp. 1053-1062
    • Huang, D.1
  • 56
    • 0030856731 scopus 로고    scopus 로고
    • Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
    • Presta, L. G. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997
    • (1997) Cancer Res , vol.57 , pp. 4593-4599
    • Presta, L.G.1
  • 57
    • 57349179851 scopus 로고    scopus 로고
    • Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy
    • Sloan, B. & Scheinfeld, N. S. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Investig. Drugs 9, 1324-1335 (2008
    • (2008) Curr. Opin. Investig. Drugs , vol.9 , pp. 1324-1335
    • Sloan, B.1    Scheinfeld, N.S.2
  • 58
    • 79551717184 scopus 로고    scopus 로고
    • Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
    • Rini, B. I. et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117, 758-767 (2011
    • (2011) Cancer , vol.117 , pp. 758-767
    • Rini, B.I.1
  • 59
    • 82755183572 scopus 로고    scopus 로고
    • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (axis): A randomised phase 3 trial
    • Rini, B. I. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 378, 1931-1939 (2011
    • (2011) Lancet , vol.378 , pp. 1931-1939
    • Rini, B.I.1
  • 60
    • 67749111502 scopus 로고    scopus 로고
    • The lkb1-ampk pathway: Metabolism and growth control in tumour suppression
    • Shackelford, D. B. & Shaw, R. J. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9, 563-575 (2009
    • (2009) Nat. Rev. Cancer , vol.9 , pp. 563-575
    • Shackelford, D.B.1    Shaw, R.J.2
  • 61
    • 77952773418 scopus 로고    scopus 로고
    • VHL and HIF signalling in renal cell carcinogenesis
    • Baldewijns, M. M. et al. VHL and HIF signalling in renal cell carcinogenesis. J. Pathol. 221, 125-138 (2010
    • (2010) J. Pathol , vol.221 , pp. 125-138
    • Baldewijns, M.M.1
  • 62
    • 33845309430 scopus 로고    scopus 로고
    • Activation of the mTOR signaling pathway in renal clear cell carcinoma
    • Robb, V. A., Karbowniczek, M., Klein-Szanto, A. J. & Henske, E. P. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J. Urol. 177, 346-352 (2007
    • (2007) J. Urol , vol.177 , pp. 346-352
    • Robb, V.A.1    Karbowniczek, M.2    Klein-Szanto, A.J.3    Henske, E.P.4
  • 63
    • 0028072991 scopus 로고
    • Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
    • Herman, J. G. et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700-9704 (1994
    • (1994) Proc. Natl Acad. Sci. USA , vol.91 , pp. 9700-9704
    • Herman, J.G.1
  • 64
    • 0036401042 scopus 로고    scopus 로고
    • Design and discovery of small molecules targeting raf-1 kinase
    • Lowinger, T. B., Riedl, B., Dumas, J. & Smith, R. A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharmacol. Des. 8, 2269-2278 (2002
    • (2002) Curr. Pharmacol. Des , vol.8 , pp. 2269-2278
    • Lowinger, T.B.1    Riedl, B.2    Dumas, J.3    Smith, R.A.4
  • 65
    • 12244301581 scopus 로고    scopus 로고
    • In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
    • Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003
    • (2003) Clin. Cancer Res , vol.9 , pp. 327-337
    • Mendel, D.B.1
  • 66
    • 67651232490 scopus 로고    scopus 로고
    • Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib
    • Solowiej, J. et al. Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib. Biochemistry 48, 7019-7031 (2009
    • (2009) Biochemistry , vol.48 , pp. 7019-7031
    • Solowiej, J.1
  • 67
    • 42249108682 scopus 로고    scopus 로고
    • Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway
    • Kent, D. et al. Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway. Clin. Cancer Res. 14, 1926-1930 (2008
    • (2008) Clin. Cancer Res , vol.14 , pp. 1926-1930
    • Kent, D.1
  • 68
    • 4544302751 scopus 로고    scopus 로고
    • Switching on kinases: Oncogenic activation of BRAF and the PDGFR family
    • Dibb, N. J., Dilworth, S. M. & Mol, C. D. Switching on kinases: Oncogenic activation of BRAF and the PDGFR family. Nat. Rev. Cancer 4, 718-727 (2004
    • (2004) Nat. Rev. Cancer , vol.4 , pp. 718-727
    • Dibb, N.J.1    Dilworth, S.M.2    Mol, C.D.3
  • 69
    • 80053580433 scopus 로고    scopus 로고
    • The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models
    • Gril, B. et al. The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. PLoS ONE 6, e25625 (2011
    • (2011) PLoS ONE , vol.6
    • Gril, B.1
  • 70
    • 80655129639 scopus 로고    scopus 로고
    • Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy
    • Inoue, H., Hwang, S. H., Wecksler, A. T., Hammock, B. D. & Weiss, R. H. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol. Ther. 12, 827-836 (2011
    • (2011) Cancer Biol. Ther , vol.12 , pp. 827-836
    • Inoue, H.1    Hwang, S.H.2    Wecksler, A.T.3    Hammock, B.D.4    Weiss, R.H.5
  • 71
    • 33845313947 scopus 로고    scopus 로고
    • P21 is a prognostic marker for renal cell carcinoma: Implications for novel therapeutic approaches
    • Weiss, R. H. et al. p21 is a prognostic marker for renal cell carcinoma: Implications for novel therapeutic approaches. J. Urol. 177, 63-69 (2007
    • (2007) J. Urol , vol.177 , pp. 63-69
    • Weiss, R.H.1
  • 72
    • 44649118573 scopus 로고    scopus 로고
    • Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53
    • Park, S. H., Park, J. Y. & Weiss, R. H. Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. J. Urol. 180, 352-360 (2008
    • (2008) J. Urol , vol.180 , pp. 352-360
    • Park, S.H.1    Park, J.Y.2    Weiss, R.H.3
  • 73
    • 84862882003 scopus 로고    scopus 로고
    • Tumor immunotherapy directed at PD-1
    • Ribas, A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366, 2517-2519 (2012
    • (2012) N. Engl. J. Med , vol.366 , pp. 2517-2519
    • Ribas, A.1
  • 74
    • 34247241169 scopus 로고    scopus 로고
    • Renal tubular epithelial expression of the coinhibitory molecule b7-dc (programmed death-1 ligand
    • Zhang, J. et al. Renal tubular epithelial expression of the coinhibitory molecule B7-DC (programmed death-1 ligand). J. Nephrol. 19, 429-438 (2006
    • (2006) J. Nephrol , vol.19 , pp. 429-438
    • Zhang, J.1
  • 75
    • 33645736792 scopus 로고    scopus 로고
    • Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
    • Thompson, R. H. et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66, 3381-3385 (2006
    • (2006) Cancer Res , vol.66 , pp. 3381-3385
    • Thompson, R.H.1
  • 76
    • 34250177269 scopus 로고    scopus 로고
    • PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
    • Thompson, R. H. et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 13, 1757-1761 (2007
    • (2007) Clin. Cancer Res , vol.13 , pp. 1757-1761
    • Thompson, R.H.1
  • 77
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
    • (2012) N. Engl. J. Med , vol.366 , pp. 2443-2454
    • Topalian, S.L.1
  • 78
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012
    • (2012) N. Engl. J. Med , vol.366 , pp. 2455-2465
    • Brahmer, J.R.1
  • 79
    • 49649114804 scopus 로고    scopus 로고
    • Phase I Safety And Pharmacokinetic Study Of CT-011 A Humanized Antibody Interacting With PD-2011 1, in patients with advanced hematologic malignancies
    • Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044-3051 (2008
    • (2008) Clin. Cancer Res , vol.14 , pp. 3044-3051
    • Berger, R.1
  • 80
    • 77954899030 scopus 로고    scopus 로고
    • Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
    • Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010
    • (2010) J. Clin. Oncol , vol.28 , pp. 3167-3175
    • Brahmer, J.R.1
  • 81
    • 84880292389 scopus 로고    scopus 로고
    • US National Library Of Medicine
    • US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/record/NCT01441765 (2013
    • (2013) Clinical Trials.Gov Online
  • 83
    • 0032142918 scopus 로고    scopus 로고
    • Roles of histone acetyltransferases and deacetylases in gene regulation
    • Kuo, M. H. & Allis, C. D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20, 615-626 (1998
    • (1998) Bioessays , vol.20 , pp. 615-626
    • Kuo, M.H.1    Allis, C.D.2
  • 84
    • 68949212379 scopus 로고    scopus 로고
    • Lysine acetylation targets protein complexes and co-regulates major cellular functions
    • Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-840 (2009
    • (2009) Science , vol.325 , pp. 834-840
    • Choudhary, C.1
  • 85
    • 34248208217 scopus 로고    scopus 로고
    • Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity
    • Harms, K. L. & Chen, X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 67, 3145-3152 (2007
    • (2007) Cancer Res , vol.67 , pp. 3145-3152
    • Harms, K.L.1    Chen, X.2
  • 86
    • 34447509697 scopus 로고    scopus 로고
    • Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
    • Duvic, M. & Vu, J. Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Investig. Drugs 16, 1111-1120 (2007
    • (2007) Expert Opin. Investig. Drugs , vol.16 , pp. 1111-1120
    • Duvic, M.1    Vu, J.2
  • 87
    • 49349098483 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
    • Carew, J. S., Giles, F. J. & Nawrocki, S. T. Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269, 7-17 (2008
    • (2008) Cancer Lett , vol.269 , pp. 7-17
    • Carew, J.S.1    Giles, F.J.2    Nawrocki, S.T.3
  • 88
    • 59349103985 scopus 로고    scopus 로고
    • Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
    • Fritzsche, F. R. et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8, 381 (2008
    • (2008) BMC Cancer , vol.8 , pp. 381
    • Fritzsche, F.R.1
  • 89
    • 72949118694 scopus 로고    scopus 로고
    • The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo
    • Jones, J. et al. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J. Cell. Mol. Med. 13, 2376-2385 (2009
    • (2009) J. Cell. Mol. Med , vol.13 , pp. 2376-2385
    • Jones, J.1
  • 90
    • 74949089953 scopus 로고    scopus 로고
    • Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels
    • Mahalingam, D. et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res. 16, 141-153 (2010
    • (2010) Clin. Cancer Res , vol.16 , pp. 141-153
    • Mahalingam, D.1
  • 91
    • 84873097735 scopus 로고    scopus 로고
    • A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer
    • Dasari, A. et al. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest. New Drugs 1, 115-125 (2012
    • (2012) Invest. New Drugs , vol.1 , pp. 115-125
    • Dasari, A.1
  • 92
    • 84856403025 scopus 로고    scopus 로고
    • Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models
    • Shen, L. et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE 7, e30815 (2012
    • (2012) PLoS ONE , vol.7
    • Shen, L.1
  • 93
    • 31344453943 scopus 로고    scopus 로고
    • Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention
    • Whiteside, T. L. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Sem. Cancer Biol. 16, 3-15 (2006
    • (2006) Sem. Cancer Biol , vol.16 , pp. 3-15
    • Whiteside, T.L.1
  • 94
    • 61649105802 scopus 로고    scopus 로고
    • CRM1-mediated nuclear export of proteins and drug resistance in cancer
    • Turner, J. G. & Sullivan, D. M. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr. Med. Chem. 15, 2648-2655 (2008
    • (2008) Curr. Med. Chem , vol.15 , pp. 2648-2655
    • Turner, J.G.1    Sullivan, D.M.2
  • 95
    • 77953617671 scopus 로고    scopus 로고
    • An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1
    • Koyama, M. & Matsuura, Y. An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1. EMBO J. 29, 2002-2013 (2010
    • (2010) EMBO J. , vol.29 , pp. 2002-2013
    • Koyama, M.1    Matsuura, Y.2
  • 96
    • 77951985216 scopus 로고    scopus 로고
    • Examination of the expanding pathways for the regulation of p21 expression and activity
    • Jung, Y. S., Qian, Y. & Chen, X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell. Signal. 22, 1003-1012 (2010
    • (2010) Cell. Signal , vol.22 , pp. 1003-1012
    • Jung, Y.S.1    Qian, Y.2    Chen, X.3
  • 97
    • 42149140616 scopus 로고    scopus 로고
    • Expression of the nuclear export protein chromosomal region maintenanceexportin 1xpo1 is a prognostic factor in human ovarian cancer
    • Noske, A. et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 112, 1733-1743 (2008
    • (2008) Cancer , vol.112 , pp. 1733-1743
    • Noske, A.1
  • 98
    • 62449215108 scopus 로고    scopus 로고
    • The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation
    • van der Watt, P. J. et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int. J. Cancer 124, 1829-1840 (2009
    • (2009) Int. J. Cancer , vol.124 , pp. 1829-1840
    • Van Der Watt, P.J.1
  • 99
    • 80053619765 scopus 로고    scopus 로고
    • Cbs9106 is a novel reversible oral crm1 inhibitor with crm1 degrading activity
    • Sakakibara, K. et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 14, 3922-3931 (2011
    • (2011) Blood , vol.14 , pp. 3922-3931
    • Sakakibara, K.1
  • 100
    • 79959619518 scopus 로고    scopus 로고
    • P53-dependent anticancer effects of leptomycin B on lung adenocarcinoma
    • Shao, C. et al. p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother. Pharmacol. 67, 1369-1380 (2011
    • (2011) Cancer Chemother. Pharmacol , vol.67 , pp. 1369-1380
    • Shao, C.1
  • 101
    • 84858005605 scopus 로고    scopus 로고
    • Nuclear export of proteins and drug resistance in cancer
    • Turner, J. G., Dawson, J. & Sullivan, D. M. Nuclear export of proteins and drug resistance in cancer. Biochem. Pharmacol. 83, 1021-1032 (2012
    • (2012) Biochem. Pharmacol , vol.83 , pp. 1021-1032
    • Turner, J.G.1    Dawson, J.2    Sullivan, D.M.3
  • 103
    • 84877601009 scopus 로고    scopus 로고
    • Crm1 blockade by selective inhibitors of nuclear export (sine) attenuates kidney cancer growth
    • doi:10.1016/j.juro.2012.10.018
    • Inoue, H. et al. CRM1 Blockade by Selective Inhibitors of Nuclear Export (SINE) attenuates Kidney Cancer Growth. J. Urol. doi:10.1016/j.juro.2012.10.018
    • J. Urol
    • Inoue, H.1
  • 105
    • 84861726854 scopus 로고    scopus 로고
    • ClinicalTrials.gov [online
    • US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01607892?term=NCT01607892&rank=1 (2012
    • (2012) US National Library Of Medicine
  • 106
    • 84861726854 scopus 로고    scopus 로고
    • ClinicalTrials.gov [online
    • US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01607905?term=NCT01607905&rank=1 (2012
    • (2012) US National Library Of Medicine
  • 108
    • 37549043546 scopus 로고    scopus 로고
    • Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma
    • Klatte, T. et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin. Cancer Res. 13, 7388-7393 (2007
    • (2007) Clin. Cancer Res , vol.13 , pp. 7388-7393
    • Klatte, T.1
  • 109
    • 84856246091 scopus 로고    scopus 로고
    • ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma
    • Carew, J. S. et al. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. PLoS ONE 7, e31120 (2012
    • (2012) PLoS ONE , vol.7
    • Carew, J.S.1
  • 110
    • 0025132245 scopus 로고
    • Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
    • Issemann, I. & Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650 (1990
    • (1990) Nature , vol.347 , pp. 645-650
    • Issemann, I.1    Green, S.2
  • 111
    • 73649141006 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes
    • Ribet, C. et al. Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes. Endocrinology 151, 123-133 (2010
    • (2010) Endocrinology , vol.151 , pp. 123-133
    • Ribet, C.1
  • 112
    • 33744797915 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt
    • Grabacka, M., Plonka, P. M., Urbanska, K. & Reiss, K. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin. Cancer Res. 12, 3028-3036 (2006
    • (2006) Clin. Cancer Res , vol.12 , pp. 3028-3036
    • Grabacka, M.1    Plonka, P.M.2    Urbanska, K.3    Reiss, K.4
  • 113
    • 36049041867 scopus 로고    scopus 로고
    • Analysis of PPAR alpha function in human kidney cell line using siRNA
    • Tachibana, K. et al. Analysis of PPAR alpha function in human kidney cell line using siRNA. Nucleic Acids Symp. Ser. (Oxf.) 50, 257-258 (2006
    • (2006) Nucleic Acids Symp. Ser. (Oxf , vol.50 , pp. 257-258
    • Tachibana, K.1
  • 114
    • 26044475136 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor-alpha and liver cancer: Where do we stand? J
    • Peters, J. M., Cheung, C. & Gonzalez, F. J. Peroxisome proliferator-activated receptor-alpha and liver cancer: Where do we stand? J. Mol. Med. 83, 774-785 (2005
    • (2005) Mol. Med , vol.83 , pp. 774-785
    • Peters, J.M.1    Cheung, C.2    Gonzalez, F.J.3
  • 115
    • 84863727312 scopus 로고    scopus 로고
    • Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis
    • Ganti, S. et al. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res. 14, 3471-3479 (2012
    • (2012) Cancer Res , vol.14 , pp. 3471-3479
    • Ganti, S.1
  • 116
    • 0036256981 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor beta expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin
    • Suchanek, K. M. May, F. J., Lee, W. J., Holman, N. A. & Roberts-Thomson, S. J. Peroxisome proliferator-activated receptor beta expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin. Int. J. Cell Biochem. Biol. 34, 1051-1058 (2002
    • (2002) Int. J. Cell Biochem. Biol , vol.34 , pp. 1051-1058
    • Suchanek, K.M.1    May, F.J.2    Lee, W.J.3    Holman, N.A.4    Roberts-Thomson, S.J.5
  • 117
    • 0036330419 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231
    • Suchanek, K. M. et al. Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol. Carcinogen. 34, 165-171 (2002
    • (2002) Mol. Carcinogen , vol.34 , pp. 165-171
    • Suchanek, K.M.1
  • 118
    • 40949118437 scopus 로고    scopus 로고
    • Temsirolimus, an inhibitor of mammalian target of rapamycin
    • Rini, B. I. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin. Cancer Res. 14, 1286-1290 (2008
    • (2008) Clin. Cancer Res , vol.14 , pp. 1286-1290
    • Rini, B.I.1
  • 119
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
    • Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1
  • 120
    • 84874851836 scopus 로고    scopus 로고
    • Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma
    • doi:10.1158/1078-0432.CCR-12-2885
    • Angevin, E. et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-12-2885
    • Clin. Cancer Res
    • Angevin, E.1
  • 121
    • 83255162603 scopus 로고    scopus 로고
    • First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors
    • Yap, T. A. et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 29, 4688-4695 (2011
    • (2011) J. Clin. Oncol , vol.29 , pp. 4688-4695
    • Yap, T.A.1
  • 122
    • 84859416603 scopus 로고    scopus 로고
    • Novel therapies for metastatic renal cell carcinoma: Efforts to expand beyond the VEGF/mTOR signaling paradigm
    • Pal, S. K. et al. Novel therapies for metastatic renal cell carcinoma: Efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol. Cancer Ther. 11, 526-537 (2012
    • (2012) Mol. Cancer Ther , vol.11 , pp. 526-537
    • Pal, S.K.1
  • 123
    • 0242525657 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors
    • Dittrich, C. et al. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin. Cancer Res. 9, 5195-5204 (2003
    • (2003) Clin. Cancer Res , vol.9 , pp. 5195-5204
    • Dittrich, C.1
  • 124
    • 77950797736 scopus 로고    scopus 로고
    • Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates
    • Underiner, T. L., Herbertz, T. & Miknyoczki, S. J. Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates. Anticancer Agents Med. Chem. 10, 7-27 (2010
    • (2010) Anticancer Agents Med. Chem , vol.10 , pp. 7-27
    • Underiner, T.L.1    Herbertz, T.2    Miknyoczki, S.J.3
  • 125
    • 84867985179 scopus 로고    scopus 로고
    • US National Library Of Medicine
    • US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01391130?term=NCT01391130&rank=1 (2012
    • (2012) ClinicalTrials.Gov Online
  • 126
    • 84864018642 scopus 로고    scopus 로고
    • Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors
    • Tolcher, A. W. et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J. Clin. Oncol. 30, 2348-2353 (2012
    • (2012) J. Clin. Oncol , vol.30 , pp. 2348-2353
    • Tolcher, A.W.1
  • 127
    • 84873097735 scopus 로고    scopus 로고
    • A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer
    • Dasari, A. et al. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest. New Drugs 31, 115-125 (2013
    • (2013) Invest. New Drugs , vol.31 , pp. 115-125
    • Dasari, A.1
  • 128
    • 77649171884 scopus 로고    scopus 로고
    • Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
    • Tan, J., Cang, S., Ma, Y., Petrillo, R. L. & Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 3, 5 (2010
    • (2010) J. Hematol. Oncol. 3 , vol.5
    • Tan, J.1    Cang, S.2    Ma, Y.3    Petrillo, R.L.4    Liu, D.5
  • 129
    • 77649106272 scopus 로고    scopus 로고
    • A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma
    • Huang, H. et al. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 16, 1634-1641 (2010
    • (2010) Clin. Cancer Res , vol.16 , pp. 1634-1641
    • Huang, H.1
  • 130
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 26, 2443-2454 (2012
    • (2012) N. Engl. J. Med , vol.26 , pp. 2443-2454
    • Topalian, S.L.1
  • 131
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 26, 2455-2465 (2012
    • (2012) N. Engl. J. Med , vol.26 , pp. 2455-2465
    • Brahmer, J.R.1
  • 132
    • 84867985179 scopus 로고    scopus 로고
    • US National Library Of Medicine
    • US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00620594?term=NCT00620594&rank=1 (2012
    • (2012) ClinicalTrials.Gov Online
  • 133
    • 84867985179 scopus 로고    scopus 로고
    • US National Library Of Medicine
    • US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00854152?term=NCT00854152&rank=1 (2012
    • (2012) ClinicalTrials.Gov [Online
  • 134
    • 4644304196 scopus 로고    scopus 로고
    • Phase II trial of bortezomib for patients with advanced renal cell carcinoma
    • Kondagunta, G. V. et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol. 22, 3720-3725 (2004
    • (2004) J. Clin. Oncol , vol.22 , pp. 3720-3725
    • Kondagunta, G.V.1
  • 135
    • 84876086360 scopus 로고    scopus 로고
    • US National Library Of Medicine
    • US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00891280?term=NCT00891280&rank=1 (2011
    • (2011) ClinicalTrials.Gov [Online
  • 136
    • 84867985179 scopus 로고    scopus 로고
    • US National Library Of Medicine
    • US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01609556?term=NCT01609556&rank=1 (2012
    • (2012) ClinicalTrials.Gov [Online
  • 137
    • 84867985179 scopus 로고    scopus 로고
    • US National Library Of Medicine
    • US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00369200?term=NCT00369200&rank=1 (2012
    • (2012) ClinicalTrials.Gov [Online


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.